Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01630811 · ClinicalTrials.gov registry record · Phase 2
Nuedexta for the Treatment of Adults With Autism
A Phase 2 study, sponsored by Sutter Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01630811 is a Phase 2 study that has completed, run by Sutter Health. The registered enrollment target is 13 participants.
The verdict
NCT01630811, a Phase 2 study, has completed, sponsored by Sutter Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
Primary: Demonstrate reduced frequency and intensity of maladaptive behaviors as measured by the Aberrant Behavior Checklist (ABC) Irritability subscale in subjects given Nuedexta 8 weeks over subjects given placebo. Secondary: Demonstrate a trend towards reduced aggressive behavior as measured by Overt Aggression Scale (OAS).
Interventions
- OTHER Placebo
- DRUG Nuedexta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-01-24 |
| Est. Completion | 2015-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01630811
The ClinicalTrials.gov registry entry for NCT01630811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sutter Health, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01630811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01630811 about?
NCT01630811 is a clinical study titled "Nuedexta for the Treatment of Adults With Autism". Primary: Demonstrate reduced frequency and intensity of maladaptive behaviors as measured by the Aberrant Behavior Checklist (ABC) Irritability subscale in subjects given Nuedexta 8 weeks over subjects given placebo. Secondary: Demonstrate a trend towards reduced aggressive behavior as measured by ...
What is the current status of trial NCT01630811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2012-01-24. Estimated completion is 2015-12-15.
What interventions are being tested in trial NCT01630811?
The interventions under investigation include: Placebo (OTHER), Nuedexta (DRUG).
Who is sponsoring clinical trial NCT01630811?
This trial is sponsored by Sutter Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.